All Articles
View Report
Q Diaceutics' Jordan Clark on industry, FDA gap on Rx/Dx codevelopment principles

Q Diaceutics' Jordan Clark on industry, FDA gap on Rx/Dx codevelopment principles

28 February, 2017

Jordan Clark discusses the FDA draft guidance of 2016, which outlines the principles for simultaneously developing a drug and diagnostic for companies planning a treatment that relies on a test for its use.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.